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Aim: The aim of this study is to compare the safety and efficacy of Sirolimus (SES), Paclitaxel (PES), EPC capture (ECS), Zotarolimus (ZES-R/ 
Endeavor Resolute), BiolimusA9 (BES) and Everolimus-eluting stent (EES) on the outcome of percutaneous coronary intervention in patients with 
diabetes mellitus (DM).
Methods: A prospective analysis of 2972 patients with DM (808 SES, 720 PES, 299 ECS, 404 ZES-R, 320 BES, 421 EES) in six high volume Asian 
centers after successful stenting was performed. The study endpoints were major adverse cardiac events (MACE) at 30 days, 12 and 24 months and 
restenosis rate and target lesion revascularization (TLR) at 12 and 24 months.
Results: See table for clinical results.
Conclusion: The use of drug-eluting stents in patient with DM was safe with low acute complication. Patients treated with BES and EES showed 
lesser rate of restenosis compared with PES and ECS. 
SES PES ECS ZES-R BES EES
Number of patients 808 720 299 404 320 421
Multivessel disease (%) 76.7 72.3 73.6 79.3 75.0 75.1
MACE at 30 days (%) 0.7 1.0 1.0 1.0 0.9 0.5
Lesion length (mean: mm) 25.4 23.9 26.2 28.3* 29.9* 28.8*
Lesion type: % of B2, C (%) 42.6 47.5 48.8 54.5 52.8 52.5
RD at baseline (mean: mm) 2.75 2.69 2.70 2.73 2.70 2.69
12 months MLD (mean: mm) 2.51 2.34 2.00 2.52 2.56 2.55
Restenosis rate 10.1 12.8 26.4 12.6 7.8* 6.7*
TLR 8.9 11.0 23.1 9.9 5.6* 4.4*
24 months MLD (mean: mm) 2.40 2.38 1.88 2.43 2.52 2.52
Restenosis rate 12.1 12.6 32.1 11.9 8.8* 7.8*
TLR 10.2 14.0 29.4 9.9 7.5* 6.7*
MLD: minimum lumen diameter, RD: reference diameter, *p<0.05 vs. ECS and PES.
